US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, on Wednesday announced positive top-line results from a Phase 3 trial evaluating its 9-valent Human Papillomavirus (HPV) vaccine, GARDASIL 9, in Japanese males.
The vaccine demonstrated efficacy in reducing the incidence of anogenital persistent infection caused by nine HPV types.
Merck plans to submit these findings to regulatory authorities in Japan and worldwide. The company is also conducting a confirmatory Phase 3 trial to assess GARDASIL 9's effectiveness in preventing HPV-related oral persistent infection.
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Sanofi in talks to sell Opella stake
Orlance receives research grant to develop Enhanced Seasonal Influenza Vaccine
MedImmune's FluMist nasal spray influenza vaccine receives US FDA approval
Gavi signs agreement with Bavarian Nordic for Mpox vaccines
Valneva seeks label extensions for chikungunya vaccine in Europe and Canada
MinervaX and Wacker Biotech collaborate on GBS vaccine manufacturing
Merck's GARDASIL 9 shows promise in preventing HPV infection in Japanese males
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Pfizer names new Regional President for Middle East, Russia and Africa
LakeShore Biopharma names new chief executive officer
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults